V International expert forum on menopausal hormone therapy

Authors

DOI:

https://doi.org/10.18370/2309-4117.2024.71.10-18

Keywords:

resolution, International Menopause Expert Forum, menopausal hormone therapy, early and premature menopause, polycystic ovary syndrome

Abstract

On November 23, 2023, the V International Forum of Experts on Menopausal Hormone Therapy (MHT) was held. The Expert Council’s working group included leading experts in the field of endocrine gynaecology and related areas from Azerbaijan, Armenia, Georgia, Kazakhstan, Moldova, Uzbekistan, and Ukraine.
The Forum experts noted the importance of dialogue and understanding between doctor and patient, the need for interdisciplinary integration between doctors of those specialties that deal with women’s health issues. Close cooperation with related specialists who provide care to women is necessary, as they are often the ones who encounter the first manifestations of menopause in patients and can therefore refer them to an obstetrician-gynaecologist in a timely manner.
The experts reviewed the issue of cardiovascular risk and MHT and determined the following benefit/risk ratio for the cardiovascular effects of MHT:
• MHT is not recommended for women at high cardiovascular risk or with previous cardiovascular disease;
• MHT may reduce the risk of CVD-related all-cause death in women < 60 years of age and with menopause of up to 10 years;
• timely initiation of MHT (in women under 60 years of age or within 10 years of menopause) has the greatest cardiovascular health benefits.
The forum updated the Algorithm for prescribing MHT in premature and early menopause and addressed the management of women with polycystic ovary syndrome
in menopause. Since the majority of women with this syndrome are overweight and obese, they should use the most metabolically neutral drugs, i.e. those containing didrogesterone or progesterone, for MHT. MHT with didrogesterone has a favourable safety profile in relation to the most common risks of MHT: does not increase the risk of breast cancer and venous thromboembolism, has a favourable safety profile with respect to the endometrium, and does not affect metabolism.

Author Biographies

L.R. Agababyan, Samarkand Medical Institute, Samarkand

PhD, associate professor, Department of Obstetrics and Gynecology, Faculty of Doctor's Improvement

L.M. Begimbekova, Khoja Akhmet Yassawi International Kazakh-Turkish University, Shymkent

PhD, associate professor, obstetrician-gynecologist, head of the Department of Obstetrics, Gynecology and Pediatrics

L.А. Vasylchenko, SSI “Center for Innovative Medical Technologies of the NAS of Ukraine”; Polyclinic No. 2 of the State Scientific Institution "Center of Innovative Medical Technologies of the NAS of Ukraine", Kyiv

PhD, senior researcher, Department of Reproductive Health;
head of the Gynecological Department

F.A. Gafurova, Tashkent Institute of Advanced Medical Education, Tashkent

PhD, associate professor, Department of Obstetrics, Gynecology and Perinatal Medicine

MA. Gegechkori, Zurab Sabakhtarashvili Reproductive Clinic, Tbilisi

Reproductive medicine doctor, head of the Academic Research Department

H.O. Grebennikova, Institute of Reproductive Medicine; Kazakhstan Association of Sexual and Reproductive Health, Almaty

Obstetrician-gynecologist, executive director of the Kazakhstan Association of Sexual and Reproductive Health

O.L. Gromova, Bogomolets National Medical University, Kyiv

PhD, assistant professor, Obstetrics and Gynecology Department of Postgraduate Education

A.P. Dzhaimbetova, Institute of Reproductive Medicine, Almaty

Obstetrician-gynecologist, KMPA expert, UNFPA consultant

T.O. Ermolenko, Odesa National Medical University, Odesa

MD, professor, Obstetrics and Gynecology Department No. 2

O.О. Yefimenko, SI “O.M. Lukyanova Institute of Pediatrics, Obstetrics and Gynecology of the NAMS of Ukraine”, Kyiv

PhD, senior researcher, Endocrine Gynecology Department

N.F. Zakharenko, SI “O.M. Lukyanova Institute of Pediatrics, Obstetrics and Gynecology of the NAMS of Ukraine”, Kyiv

MD, professor, leading research fellow, Endocrine Gynecology Department

I.L. Kopobayeva, Karaganda Medical University; Karaganda branch of the KMPA, Karaganda

Assistant professor, Department of Obstetrics, Gynecology and Perinatology;
president of the Karaganda branch of the KMPA

N.V. Kosei, SSI “Center for Innovative Medical Technologies of the NAS of Ukraine», Kyiv

MD, professor, head of the Department of Reproductive Health

D.І. Kristesashvili, Ivane Javakhishvili Tbilisi State University; Center for Reproductive Medicine "University", Tbilisi

Professor, Department of Obstetrics, Gynecology and Reproductive Medicine of the Medical Faculty;
Vice-president of the Georgian Reproductive Health Association;
Deputy director of the Center for Reproductive Medicine "University"

L.A. Mishchenko, SI "National Scientific Center "M.D. Strazhesko Institute of Cardiology, Clinical and Regenerative Medicine” of the NAMS of Ukraine, Kyiv

MD, professor, head of the Department of Arterial Hypertension and Comorbid Pathology

G.T. Myrzabekova, Center of Molecular Medicine, Almaty

Obstetrician-gynecologist

N.Y. Pedachenko, P.L. Shupyk National University of Health Care of Ukraine, Kyiv

MD, professor, Department of Obstetrics, Gynecology and Perinatology

I.G. Persoyan, Medical Center "Asthik", Yerevan

PhD, head of the Women's Consultation, president of the Armenian Anti-Aging Medical Association, obstetrician-gynecologist, gynecologist-endocrinologist

V.I. Pyrohova, Danylo Halytsky Lviv National Medical University, Lviv

MD, head of the Obstetrics, Gynaecology and Perinatology Department, Faculty of Postgraduate Education

S.I. Reheda, SSI “Center for Innovative Medical Technologies of the NAS of Ukraine”, Kyiv

PhD, senior researcher, Reproductive Health Department, head of the Gynecology Department

N.M. Rozhkovska, Odesa National Medical University, Odesa

MD, professor, Obstetrics and Gynecology Department

K. Rustamova, Family Planning Center, Baku

Obstetrician-gynecologist, Family Planning Center, expert on evidentiary standards in obstetrics and gynecology of the Ministry of Health of Azerbaijan

H.H. Salimkhanova, Medical Center "Baku", Baku

PhD, gynecologist-endocrinologist

L.V. Stavinska, Nicolae Testemitanu State University of Medicine and Pharmacy, Chisinau

Assistant, Department of Obstetrics and Gynecology

T.F. Tatarchuk, SI “O.M. Lukyanova Institute of Pediatrics, Obstetrics and Gynecology of the NAMS of Ukraine”; SSI “Center for Innovative Medical Technologies of the NAS of Ukraine", Kyiv

MD, professor, corresponding member of the NAMS of Ukraine, deputy director for research work, head of the Endocrine Gynecology Department;
chief researcher of the Department of Reproductive Health

O.V. Trokhymovych, SI “O.M. Lukyanova Institute of Pediatrics, Obstetrics and Gynecology of the NAMS of Ukraine”, Kyiv

MD, chief researcher, Department of Family Planning

T.M. Tutchenko, SI “O.M. Lukyanova IPOG of the NAMS of Ukraine”; SSI “Center for Innovative Medical Technologies of the NAS of Ukraine", Kyiv

PhD, senior researcher of the Endocrine Gynecology Department, SI “O.M. Lukyanova IPOG of the NAMS of Ukraine”, Department of Reproductive Health of SSI “Center for Innovative Medical Technologies of the NAS of Ukraine", scientific consultant of “DILA” Medical Laboratory

T.M. Ukibasova, National Scientific Center of Motherhood and Childhood of the CF "University Medical Center", Astana

MD, professor, obstetrician-gynecologist

O.G. Yashina, Medicom Clinic, Kyiv

PhD, leading specialist

References

  1. Order of the MOH of Ukraine dated June 17, 2022 “On approval of the Unified clinical protocol of the primary, secondary (specialized), tertiary (highly specialized) medical assistance «Menopausal disorders and other disorders in perimenopausal period»” [Internet]. Kyiv: State Expert Center of the Ministry of Health of Ukraine, 2022. Available from: https://www.dec.gov.ua/mtd/menopauzalni-porushennya-ta-inshi-rozlady-v-perymenopauzalnomu-periodi/
  2. Maas AHEM, Rosano G, Cifkova R, et al. Cardiovascular health after menopause transition, pregnancy disorders, and other gynaecologic conditions: a consensus document from European cardiologists, gynaecologists, and endocrinologists. Eur Heart J. 2021 Mar 7;42(10):967–84. DOI: 10.1093/eurheartj/ehaa1044.
  3. Stevenson JC, Rioux JE, Komer L, Gelfand M. 1 and 2 mg 17beta-estradiol combined with sequential dydrogesterone have similar effects on the serum lipid profile of postmenopausal women. Climacteric. 2005;8:352–9. DOI: 10.1080/13697130500345190.
  4. Visseren FLJ, Mach F, Smulders YM, et al. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J. 2021 Sep 7;42(34):3227–337. DOI: 10.1093/eurheartj/ehab484.
  5. Fleg JL, Stone GW, Faya ZA, et al. Detection of High-Risk Atherosclerotic Plaque:Report of the NHLBI Working Group on Current Status and Future Directions. JACC Cardiovasc Imaging. 2012 September; 5(9):941–55. DOI: 10.1016/j.jcmg.2012.07.007.
  6. Giri R, Vincent AJ. Prevalence and Risk Factors of Premature Ovarian Insufficiency/Early Menopause. Semin Reprod Med. 2020;38(4–05):237–246. DOI:10.1055/s-0040-1722317
  7. Golezar S, Ramezani Tehrani F, Khazaei S, et al. The global prevalence of primary ovarian insufficiency and early menopause: a meta-analysis. Climacteric 2019;22:403–11. DOI: 10.1080/13697137.2019.1574738.
  8. Goswami D, Conway GS. Premature ovarian failure. Hum Rep Update 2005; 11 (4):391-410. DOI: 10.1093/humupd/dmi012.
  9. Baber R.J. Panay N, Fenton A; IMS Writing Group. IMS Recommendations on women’s midlife health and menopause hormone therapy. Climacteric 2016; 19:109–50. DOI: 10.3109/13697137.2015.1129166
  10. Panay N, Anderson RA, Nappi RE, et al. Premature ovarian insufficiency: an International Menopause Society White Paper. Climacteric. 2020 Oct;23(5):426–446. DOI: 10.1080/13697137.2020.1804547.
  11. Lambrinoudaki I, Paschou SA, Lumsden MA, et al. Premature ovarian insufficiency: A toolkit for the primary care physician. Maturitas. 2021;147:53-63. DOI:10.1016/j.maturitas.2020.11.004
  12. Rotterdam ESHRE/ASRM-Sponsored PCOS consensus workshop group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod 2004; 19(1): 41–7. DOI: 10.1093/humrep/deh098
  13. Helvaci N, Yildiz BO. Polycystic ovary syndrome and aging: Health implications after menopause. Maturitas. 2020 Sep:139:12–9. DOI: 10.1016/j.maturitas.2020.05.013
  14. Minooee S, Tehrani FR, Rahmati M, et al. Prediction of age at menopause in women with polycystic ovary syndrome. Climacteric. 2018;21(1):29–34. DOI:10.1080/13697137.2017.1392501
  15. Millán-de-Meer M, Luque-Ramírez M, Nattero-Chávez L, Escobar-Morreale HF. PCOS during the menopausal transition and after menopause: a systematic review and metaanalysis. Human Reprod Update. 2023 Nov 2;29(6):741-772. DOI: 10.1093/humupd/dmad015
  16. Teede HJ, Tay CT, Laven J, et al; International PCOS Network. Recommendations from the 2023 International Evidence-based Guideline for the Assessment and Management of Polycystic Ovary Syndrome. Hum Reprod. 2023 Sep 5;38(9):1655–79. DOI: 10.1093/humrep/dead156.
  17. Teede HJ, Tay CT, Laven JJE, et al. Recommendations From the 2023 International Evidence-based Guideline for the Assessment and Management of Polycystic Ovary Syndrome. J Clin Endocrinol Metab. 2023 Sep 18;108(10):2447–69. DOI: 10.1210/clinem/dgad463.
  18. Lyytinen H, Pukkala E, Ylikorkala O. Breast cancer risk in postmenopausal women using estradiol-progestogen therapy. Obstet Gynecol. 2009;113:65–73. DOI: 10.1097/AOG.0b013e31818e8cd6.
  19. Chlebowski RT, Anderson GL, Aragaki AK, et al. Association of Menopausal Hormone Therapy With Breast Cancer Incidence and Mortality During Long-term Follow-up of the Women’s Health Initiative Randomized Clinical Trials. JAMA. 2020 Jul 28;324(4):369–80. DOI: 10.1001/jama.2020.9482.
  20. Franke НR, Vermes I. Differential effects of progestogens оn breast cancer cell lines. Maturitas. 2003; 46 Suppl 1:S55-S58. DOI: 10.1016/j. maturitas.2003.09.019
  21. Fournier А, Berrino F, Clavel-Chapelon F. Unequal risks for breast cancer associated with different hormone replacement therapies: results from the E3N cohort study. Breast Cancer Res Treat 2008; 107(1):103-11. DOI: 10.1007/s10549-007-9523-x.
  22. Vinogradova Y, Coupland C, Hippisley-Cox J. Use of hormone replacement therapy and risk of breast cancer: nested case-control studies using the QResearch and CPRD databases. BMJ 2020;371:m3873. DOI: 10.1136/bmj.m3873.
  23. Ferenczy A, Gelfand MM, van de Weijer PHM, Rioux JE. Endometrial safety and bleeding patterns during a 2-year study of 1 or 2 mg 17b-estradiol combined with sequential 5–20mg dydrogesterone. Climacteric. 2002;5:26–35
  24. Vinogradova Y, Coupland C, Hippisley-Cox J. Use of hormone replacement therapy and risk of venous thromboembolism: nested case-control studies using the QResearch and CPRD databases. BMJ. 2019;364:k4810. DOI: 10.1136/bmj.k4810.
  25. Anagnostis P, Bitzer J, Cano A, et al. Menopause symptom management in women with dyslipidemias: An EMAS clinical guide. Maturitas. 2020;135:82–8. DOI: 10.1016/j.maturitas.2020.03.007.
  26. Pourhadi N, Mоrch LS, Holm EA et al. Menopausal hormone therapy and dementia: nationwide, nested case-control study. BMJ2023;381:e072770. DOI: 10.1136/bmj-2022-072770.
  27. Rapp SR, Espeland MA, Shumaker SA et al. Effect of estrogen plus progestin on global cognitive function in postmenopausal women: the Women’s Health Initiative Memory Study: a randomized controlled trial. JAMA 2003. May 28;289(20):2663–72. DOI: 10.1001/jama.289.20.2663
  28. Hodis HN, Mack WJ, Henderson VW, et al. Vascular Effects of Early versus Late Postmenopausal Treatment with Estradiol. N Engl J Med. 2016;374(13):1221–31. DOI:10.1056/NEJMoa1505241
  29. Miller VM, Naftolin F, Asthana S, et al. The Kronos Early Estrogen Prevention Study (KEEPS): what have we learned? Menopause. 2019;26(9):1071–84. DOI:10.1097/GME.0000000000001326
  30. Vinogradova Y, Dening T, Hippisley-Cox J, et al. Use of menopausal hormone therapy and risk of dementia: nested case-control studies using QResearch and CPRD databases. BMJ 2021; 375:n2182. DOI: 10.1136/bmj.n2182.
  31. Kim Y J, Soto M, Branigan G L, et al. Association between menopausal hormone therapy and risk of neurodegenerative diseases: Implications for precision hormone therapy. Alzheimers Dement (N Y). 2021 May 13;7(1):e12174. DOI: 10.1002/trc2.12174.

Downloads

Published

2024-03-15

How to Cite

Agababyan, L., Begimbekova, L., Vasylchenko, L., Gafurova, F., Gegechkori, M., Grebennikova, H., Gromova, O., Dzhaimbetova, A., Ermolenko, T., Yefimenko, O., Zakharenko, N., Kopobayeva, I., Kosei, N., Kristesashvili, D., Mishchenko, L., Myrzabekova, G., Pedachenko, N., Persoyan, I., Pyrohova, V., Reheda, S., Rozhkovska, N., Rustamova, K., Salimkhanova, H., Stavinska, L., Tatarchuk, T., Trokhymovych, O., Tutchenko, T., Ukibasova, T., & Yashina, O. (2024). V International expert forum on menopausal hormone therapy. REPRODUCTIVE ENDOCRINOLOGY, (71), 10–18. https://doi.org/10.18370/2309-4117.2024.71.10-18

Issue

No. 71 (2024)

Section

Events

License

Copyright (c) 2024 Л.Р. Агабабян, Л.М. Бегімбекова, Л.А. Васильченко, Ф.А. Гафурова, М.А. Гегечкорі, Г.О. Гребеннікова

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Authors who publish with this journal agree to the following terms:

    1. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.

    1. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.